15 Antiphospholipid Syndrome Clinical Trials in Atlanta, GA (2026)

Q: How do I join a clinical trial in Atlanta?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Atlanta research site will contact you.

Recruiting Antiphospholipid Syndrome Studies in Atlanta

NCT05237258Recruiting

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcome...

Atlanta, GANA2,300 participantsMassachusetts General Hospital

View Study Details

NCT07222761Recruiting

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

This study is researching a drug called linvoseltamab (also called "study drug") either given alone or in combination with another anti-myeloma drug called carfilzomib, compared to several standard tr...

Atlanta, GAPHASE3915 participantsRegeneron Pharmaceuticals

View Study Details

NCT02074839Recruiting

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mu...

Atlanta, GAPHASE1291 participantsInstitut de Recherches Internationales Servier

View Study Details

NCT04989803Recruiting

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma....

Atlanta, GAPHASE1247 participantsKite, A Gilead Company

View Study Details

NCT05862012Recruiting

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM)....

Atlanta, GAPHASE1200 participantsIchnos Sciences SA

View Study Details

NCT06433947Recruiting

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in ...

Atlanta, GAPHASE1130 participantsOpna Bio LLC

View Study Details

NCT06549790Recruiting

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

The aim of PERKA-812-003 study is to investigate the safety, pharmacokinetics and preliminary anti-tumor activity of treatment with NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Le...

Atlanta, GAPHASE1124 participantsNerviano Medical Sciences

View Study Details

NCT07681596Recruiting

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumuma...

Atlanta, GAPHASE1101 participantsAstraZeneca

View Study Details

NCT07075185Recruiting

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma....

Atlanta, GAPHASE170 participantsKelonia Therapeutics, Inc.

View Study Details

NCT02926690Recruiting

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast cance...

Atlanta, GAPHASE170 participantsOncoTherapy Science, Inc.

View Study Details

NCT06919900Recruiting

Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis

The primary purpose of this interventional study is to examine the overall motor learning capacity from exposure to repeated perturbations among ambulatory people with multiple sclerosis (MS). This pr...

Atlanta, GANA64 participantsGeorgia State University

View Study Details

NCT06796504Recruiting

The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study

The MS pilot study will assess the safety and investigate the remyelinating effects of the SetPoint System (study device) in adult patients with patients diagnosed with relapsing-remitting multiple sc...

Atlanta, GANA60 participantsSetPoint Medical Corporation

View Study Details

NCT05143996Recruiting

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)...

Atlanta, GAPHASE160 participantsCullinan Therapeutics Inc.

View Study Details

NCT06629428Recruiting

Effects of Ublituximab on Motor Functions in Multiple Sclerosis

The purpose of this study is to test if ublituximab changes walking functions and fall risk in people with relapsing multiple sclerosis (RMS). Twenty-five qualified people with RMS will undergo a 48-w...

Atlanta, GAEARLY_PHASE125 participantsGeorgia State University

View Study Details

NCT06376162Recruiting

Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

The primary objective of the study is to determine the recommended phase 2 dose (RP2D) of ziftomenib in combination with chemotherapy (FLA) in children with relapsed or refractory KMT2A-r, NUP98-r, or...

Atlanta, GAPHASE120 participantsPedAL BCU, LLC

View Study Details

About Antiphospholipid Syndrome Clinical Trials in Atlanta

Antiphospholipid syndrome is an autoimmune disorder that increases the risk of blood clots in arteries and veins, and pregnancy complications. It occurs when the immune system makes antibodies that attack phospholipids. Treatment primarily involves anticoagulant medications.

There are currently 15 antiphospholipid syndrome clinical trials recruiting participants in Atlanta, GA. These studies are seeking a combined 4,677 participants. Research is being sponsored by Massachusetts General Hospital, Regeneron Pharmaceuticals, Institut de Recherches Internationales Servier and 11 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Antiphospholipid Syndrome Clinical Trials in Atlanta — FAQ

Are there antiphospholipid syndrome clinical trials in Atlanta?

Yes, there are 15 antiphospholipid syndrome clinical trials currently recruiting in Atlanta, GA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Atlanta?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Atlanta research site will contact you about next steps.

Are clinical trials in Atlanta free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Atlanta studies also compensate for your time and travel.

What antiphospholipid syndrome treatments are being tested?

The 15 active trials in Atlanta are testing new therapies including novel drugs, biologics, and treatment approaches for antiphospholipid syndrome.

Data updated October 15, 2026 from ClinicalTrials.gov